Technical Analysis for FUSN - Fusion Pharmaceuticals Inc.

Grade Last Price % Change Price Change
F 8.68 -0.69% -0.06
FUSN closed down 0.69 percent on Thursday, April 22, 2021, on 12 percent of normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.

Trend Table & Recent EOD Signals

ADX Long Term Intermediate Term Short Term
Strong Down Down Down
Historical FUSN trend table...

Date Alert Name Type % Chg
1,2,3 Retracement Bearish Bearish Swing Setup 0.00%
Boomer Sell Setup Bearish Swing Setup 0.00%
Non-ADX 1,2,3,4 Bearish Bearish Swing Setup 0.00%
Narrow Range Bar Range Contraction 0.00%
NR7 Range Contraction 0.00%
NR7-2 Range Contraction 0.00%
Wide Bands Range Expansion 0.00%
Oversold Stochastic Weakness 0.00%
NR7 Range Contraction -0.69%
Wide Bands Range Expansion -0.69%
Older End-of-Day Signals for FUSN ...

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Alert Time
60 Minute Opening Range Breakout about 19 hours ago
Reversed from Down about 19 hours ago
Down 2 % about 20 hours ago
Down 1% about 20 hours ago
Possible NR7 about 20 hours ago
View Earlier Intraday Alerts

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.


Fusion Pharmaceuticals Inc. Description

Fusion Pharmaceuticals Inc., a clinical-stage oncology company, focuses on developing radiopharmaceuticals as precision medicines. The company has developed Targeted Alpha Therapies platform together with its proprietary Fast-Clear linker technology to enable us to connect alpha particle emitting isotopes to antibodies and other targeting molecules in order to selectively deliver the alpha particle payloads to tumors. Its lead product candidate is FPI-1434 that is in Phase 1 clinical trials as a monotherapy in patients with solid tumors expressing insulin-like growth factor 1 receptor. The company is also conducting additional preclinical studies of FPI-1434 in combination with approved checkpoint inhibitors and DNA damage response inhibitors to further assess the anti-tumor activity, and dosing schedule and pharmacodynamics of the combinations. In addition, it is progressing its earlier-stage product candidate, FPI-1966 into clinical development for the treatment of head and neck, and bladder cancers expressing fibroblast growth factor receptor. The company was founded in 2014 and is headquartered in Hamilton, Canada.


Sector: Healthcare
Industry: Biotechnology
Keywords: Clinical Development Solid Tumors Antibodies Cell Biology Insulin Tumors Precision Medicine Tyrosine Kinase Receptors Proteins Bladder Cancer Checkpoint Inhibitor Fibroblast Growth Factor Fibroblast Growth Factor Receptor Linker Pharmacodynamics Radiopharmaceuticals Bladder Cancers Growth Factor Linker Technology

Is FUSN a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength


Indicator Value
52 Week High 19.0
52 Week Low 8.09
Average Volume 44,323
200-Day Moving Average 12.33
50-Day Moving Average 10.85
20-Day Moving Average 9.58
10-Day Moving Average 8.80
Average True Range 0.67
ADX 32.92
+DI 8.82
-DI 24.71
Chandelier Exit (Long, 3 ATRs ) 10.47
Chandelier Exit (Short, 3 ATRs ) 10.09
Upper Bollinger Band 11.28
Lower Bollinger Band 7.88
Percent B (%b) 0.24
BandWidth 35.51
MACD Line -0.71
MACD Signal Line -0.65
MACD Histogram -0.064
Fundamentals Value
Market Cap 362.18 Million
Num Shares 41.7 Million
EPS -0.57
Price-to-Earnings (P/E) Ratio -15.16
Price-to-Sales 0.00
Price-to-Book 1.79
PEG Ratio 0.00
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 9.00
Resistance 3 (R3) 8.99 8.87 8.94
Resistance 2 (R2) 8.87 8.79 8.88 8.92
Resistance 1 (R1) 8.78 8.74 8.72 8.79 8.91
Pivot Point 8.66 8.66 8.64 8.67 8.66
Support 1 (S1) 8.57 8.58 8.51 8.58 8.45
Support 2 (S2) 8.45 8.53 8.46 8.44
Support 3 (S3) 8.36 8.45 8.42
Support 4 (S4) 8.37